Literature DB >> 8872863

Adaptive changes in the rat dopaminergic transmission following repeated lithium administration.

M Dziedzicka-Wasylewska1, M Maćkowiak, K Fijat, K Wedzony.   

Abstract

In the present study the alterations in the contents of dopamine (DA) and metabolites, as well as in the levels of mRNA coding for DA receptor D2, were determined in the rat striatum (STR) and nucleus accumbens septi (NAS), in correlation with the duration of lithium administration. Single or subchronic (3 days) administration of lithium produced less consistent effects as far as the levels of DA and metabolites are concerned; however, following 7 or 14 days of lithium administration, the DA release from terminals was significantly attenuated and the effect was more pronounced in NAS. After the same time of treatment, the increase in the levels of mRNA coding for the D2 receptor was increased; this might be interpreted as an adaptive change to the decreased dopaminergic transmission following the prolonged administration of lithium.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872863     DOI: 10.1007/BF01273357

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  42 in total

1.  Effect of lithium on brain dopamine.

Authors:  E Friedman; S Gershon
Journal:  Nature       Date:  1973-06-29       Impact factor: 49.962

2.  Effect of chronic lithium treatment on monoamine metabolism in rat brain.

Authors:  J Schubert
Journal:  Psychopharmacologia       Date:  1973-09-28

Review 3.  The catecholamine hypothesis of affective disorders: a review of supporting evidence.

Authors:  J J Schildkraut
Journal:  Am J Psychiatry       Date:  1965-11       Impact factor: 18.112

4.  Acute effects of lithium on catecholamines, serotonin, and their major metabolites in discrete brain regions.

Authors:  E Gottberg; L Grondin; T A Reader
Journal:  J Neurosci Res       Date:  1989-03       Impact factor: 4.164

5.  Striatal dopamine and motor activity changes observed shortly after lithium administration.

Authors:  M E Otero Losada; M C Rubio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-09       Impact factor: 3.000

6.  Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.

Authors:  D A Staunton; P J Magistretti; W J Shoemaker; S N Deyo; F E Bloom
Journal:  Brain Res       Date:  1982-01-28       Impact factor: 3.252

7.  Change of synaptic membrane lipid composition and fluidity by chronic administration of lithium.

Authors:  B López-Corcuera; C Giménez; C Aragón
Journal:  Biochim Biophys Acta       Date:  1988-04-22

8.  Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.

Authors:  A Pert; J E Rosenblatt; C Sivit; C B Pert; W E Bunney
Journal:  Science       Date:  1978-07-14       Impact factor: 47.728

9.  Effects of chronic lithium treatments on central dopaminergic receptor systems: G proteins as possible targets.

Authors:  M Carli; M B Anand-Srivastava; E Molina-Holgado; K M Dewar; T A Reader
Journal:  Neurochem Int       Date:  1994-01       Impact factor: 3.921

Review 10.  Chemical and physiological aspects of the actions of lithium and antidepressant drugs.

Authors:  F E Bloom; G Baetge; S Deyo; A Ettenberg; L Koda; P J Magistretti; W J Shoemaker; D A Staunton
Journal:  Neuropharmacology       Date:  1983-03       Impact factor: 5.250

View more
  5 in total

1.  Lithium suppression of tau induces brain iron accumulation and neurodegeneration.

Authors:  P Lei; S Ayton; A T Appukuttan; S Moon; J A Duce; I Volitakis; R Cherny; S J Wood; M Greenough; G Berger; C Pantelis; P McGorry; A Yung; D I Finkelstein; A I Bush
Journal:  Mol Psychiatry       Date:  2016-07-12       Impact factor: 15.992

Review 2.  Emerging targets signaling for inflammation in Parkinson's disease drug discovery.

Authors:  Rhema Chandan Khairnar; Niraj Parihar; Kedar S Prabhavalkar; Lokesh Kumar Bhatt
Journal:  Metab Brain Dis       Date:  2022-05-10       Impact factor: 3.655

3.  Chronic lithium treatment rectifies maladaptive dopamine release in the nucleus accumbens.

Authors:  Adem Can; Douglas O Frost; Roger Cachope; Joseph F Cheer; Todd D Gould
Journal:  J Neurochem       Date:  2016-10-18       Impact factor: 5.372

4.  GSK-3 in Neurodegenerative Diseases.

Authors:  Peng Lei; Scott Ayton; Ashley I Bush; Paul A Adlard
Journal:  Int J Alzheimers Dis       Date:  2011-05-04

Review 5.  Lithium and Therapeutic Targeting of GSK-3.

Authors:  Melinda E Snitow; Rahul S Bhansali; Peter S Klein
Journal:  Cells       Date:  2021-01-28       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.